PwC named a Leader in the IDC MarketScape: Worldwide Life Science R&D Decentralized Clinical Trial Consulting Services 2022

PwC has been named as a Leader in the IDC MarketScape: Worldwide Life Science R&D Decentralized Clinical Trial (DCT) Consulting Services 2022 Vendor Assessment (September 2022, IDC #US49648822). 

Commenting on PwC, the IDC MarketScape report states, ‘PwC’s key differentiators include its expertise in DCT strategy and implementation support, its integrated approach across technology and management consulting, and its multidisciplinary team of over 100 consultants. PwC has provided inputs to protocol design for multiple studies.’

Ian Shafer, Principal, Pharma R&D Advisory Practice, PwC US, said, ‘We are thrilled to be named a leader in Life Science R&D Decentralized Clinical Trial Consulting Services by the IDC MarketScape. Working closely with our clients, ranging from global biopharmaceutical organizations to healthcare companies entering clinical research, we continue to reimagine the future of clinical trials, accelerate development of new medicines, and improve access to clinical trials.’

_{About IDC MarketScape}

_{IDC MarketScape vendor assessment model is designed to provide an overview of the competitive fitness of ICT (information and communications technology) suppliers in a given market. The research methodology utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each vendor’s position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of IT and telecommunications vendors can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective vendors.}